REVOLUTION Medicines (RVMD)

Executive Summary

REVOLUTION Medicines is a precision oncology company pioneering novel tri-complex inhibitors to target RAS-driven cancers, historically considered undruggable. With a market cap exceeding $18 billion, the company's pipeline centers on multiple RAS(ON) inhibitors, including RMC-6236 and daraxonrasib, across a range of solid tumors. Key programs include Phase 3 trials for daraxonrasib in pancreatic cancer and NSCLC, as well as Phase 1/2 combination studies. The company's innovative platform has generated significant investor interest, but regulatory and clinical risks remain. Near-term catalysts include pivotal data readouts and potential regulatory submissions that could validate the platform and drive substantial value.

Upcoming Catalysts (preview)

• H2 2027Phase 3 data readout for daraxonrasib in pancreatic cancer (NCT07252232)60% success
• H1 2028Phase 3 data readout for daraxonrasib + docetaxel in NSCLC (NCT06881784)55% success
• H2 2026Initial Phase 1/2 efficacy data for RMC-6236 combination in colorectal cancer (NCT06445062)40% success